AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$MRNA

Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook Improves

Moderna (MRNA) reported Q3 2026 earnings of $0.38 per share, beating estimates, with revenue up 29% YoY to $1.31B. The company raised its full-year revenue growth forecast to 15-25% and increased its projected year-end cash balance. Shares jumped 10% on the news, driven by strong international COVID-19 vaccine sales and lower R&D expenses.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 1:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 1:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Moderna Shares Jump 10% as Q3 Earnings Beat Forecasts and Revenue Outlook Improves — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The earnings beat and guidance raise suggest stronger cash flow, enabling further R&D investment and possible M&A activity in the biotech space.

02

Market read

The combination of earnings beat, guidance uplift, and regulatory approval created a material price move, making the news highly relevant for traders.

03

What to watch

Potential headwinds from competition in flu vaccines and upcoming regulatory reviews for intismeran.

Relevance 9/10Novelty 9/10Timing: today, pre‑market reaction

Background

Moderna's Q3 2026 results show a turnaround to profitability driven by international COVID‑19 vaccine sales and cost cuts, alongside new product milestones.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna reported Q3 earnings beat, raised full‑year revenue growth guidance to 15‑25% and announced FDA approval for its seasonal flu vaccine, driving a 10% share jump.

Expected impact

likely upward pressure as investors price in higher revenue growth and new product approval

Evidence & confidence

Earnings beat, guidance raise, and regulatory approval are fresh, material facts that moved the stock 10% intraday.

Market effects

Sector

Biotech sector may benefit from renewed investor confidence in vaccine and oncology pipelines.

Regional

International vaccine sales boost Moderna's exposure to emerging markets.

Global

FDA approval and earnings beat could influence broader biotech sentiment worldwide.

Counterpoint

What could challenge this read

Some analysts may question the sustainability of revenue growth if COVID‑19 vaccine demand continues to wane.

Key entities

  • Company
    Moderna Inc.

    Biotech firm reporting Q3 earnings and FDA approval.

  • Regulator
    FDA

    Approved Moderna's seasonal influenza vaccine mFLUSIVA.

Read at source← All news

StoryModerna posts Q3 profit, beats revenue estimates and lifts 2026 growth outlook

Also covered by

5 outlets

Related articles

$MRNAHighAI 9/10

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna (MRNA) reported Q3 2026 EPS of $0.38, beating estimates by $1.48. Revenue rose 29.2% YoY to $1.31B, driven by international COVID-19 vaccine sales. The company raised its 2026 sales outlook to 15-25% growth and reduced R&D spending plans. Shares rose in pre-market trading. Key products include mFlusiva and mCoflu vaccines, with mixed pipeline results.

zacks.com
$MRNAMedAI 8/10

WHO adds two more Ebola vaccines to clinical trial

WHO adds two Ebola vaccines, ChAdOx1 and mRNA-1469, to clinical trial in DRC. Developed by Oxford/Serum Institute and Moderna, they target the Bundibugyo virus. WHO's advisory group recommended further evaluation. Trial led by Institut National de Recherche Biomédicale and others. Current outbreak has caused over 4,600 cases and 2,100 deaths.

finance.yahoo.com
$MRNAMedAI 8/10

Moderna enjoys stable vaccine sales thanks to global COVID uptake

Moderna reported a 29% revenue increase to $1.3 billion for the quarter, driven by global COVID-19 vaccine sales. CFO Jamey Mock attributed growth to higher uptake of mNEXSPIKE and Spikevax. U.S. revenue is declining, but global expansion is leading sales. Moderna raised annual revenue expectations to 15-25%. Analysts noted strong vaccine sales and potential market share gains in the EU post-Pfizer's contract expiration.

biospace.com
$MRNAHighAI 8/10

What Moderna (MRNA) Said on Its Q3 Earnings Call

Moderna reported a 27% drop in R&D expenses to $583M in Q3, while SG&A expenses rose 5% to $282M. The company reduced its full-year R&D and capital expenditure estimates. Cash and investments increased to $8B. Moderna expects year-end cash of $8.1B-$8.3B. It announced progress in melanoma, renal cell carcinoma, and pancreatic cancer studies, and received FDA approval for its flu vaccine mFLUSIVA. The norovirus vaccine candidate did not meet interim success criteria.

finance.yahoo.com